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Summary and Easton 1995), The gene has been mapped to 17q 12-
We have identified 79 imitations in BRCA1 in a set of <*21 <Ha11 f  nL } 990\ ^ iki, et,aL {994J '  *ncl f rm: |inc 
643 Dutch and 23 Belgian hereditary breast and ovarian mutations iaye been identified in ^3( lamihes, icy
cancer families collected either for research or for clini- m;e nearl1y “ M ^ o i d y  distributed over the coding re­
cai diagnostic purposes. Twenty-eight distinct mutations p oili > ^ 5 /)  ate Ira mes nk* ot nonsense mutations 
have been observed, 18 of them not previously reported ^ t o  piemia tin e teinnnatioii ot pi otein ti ons anon
and 12 of them occurring more than once. Most conspic­
uously, a 2804delAA mutation has been found 19 times 
and has never been reported outside the Netherlands. A 
common haplotype spanning 2*375 kb could be idcnti-
(Shattuck-Eidens et* al. 1995; Couch et al. 1996), À num
ber of mutations have been found repeatedly, reducing 
the number of distinct mutations to ~  130. Two of these, 
the 185delAG mutation and the 5382insC mutation,
fied for each of the nine examined recurrent mutations, 1 ^  ° f  mutations thus lai lepoited
indicating the presence of multiple BRCA1 founder mu-  ^ ^  .e / ^
tations in the Dutch population. The 2804delAA muta­
tion has been estimated to have originated ~ 3 2  genera­
tions ago. No specific breast or ovarian cancer
The incidence of specific mutations seems to he 
strongly dependent on the population from which the 
breast' cancer families were ascertained, Thus the 
185delA G  mutation was found mainly in families ofphenotype could be assigned to any of the common mu- , . ,
tations, and the ovarian cancer incidence among 18 fam- cenazi Jewish or igni ( onin el al. ) ). ), Subsc«
ilies with the 2804delA A  mutation was heterogeneous, quent y, a cantei frequency o( ^ I /o was estimated
lor the 185delACi mutation am ong Ashkenazi Jews
unselected for the presence of either breast cancer or 
a positive family history (Struewing et al. I 995 í/; Roa 
et al. 1 996), eight times the incidence of all mutations 
together in the general population (l;ord et al. 1995),
Introduction
BRCAI is one of several genes that predisposes strongly 
to the development of breast and ovarian cancer (Ford
Specific m utations also have been recurrently detected
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age at origin has been estimated for only a few of 
them (Neuhausen et al. 1996).
To further explore the existence of population-specific 
BRCA1 mutations, we have screened > 650  families of 
Dutch and Belgian origin for the presence of mutations. 
Our results are in agreement with the concept that the 
incidence of specific BRCA1 mutations can be strongly 
influenced by the geographic origin of the study popula­
tion and indicate that this is due to the presence of one 
or more founder mutations.
Subjects and Methods
Family Ascertainment
Families were accrued essentially through two routes: 
(1) as “research35 families, which were ascertained by the 
Netherlands Foundation for the Detection of Hereditary 
Tumors and from which blood samples were taken by 
the Department of Human Genetics in the Leiden Uni­
versity Medical Center, and (2) as “counseling” families, 
which were recruited by self- or physician referral to a 
family cancer clinic or clinical genetics department in 
either Amsterdam, Brussels, Groningen, Leiden, Maas­
tricht, Nijmegen, Rotterdam, or Utrecht. Research fami­
lies were sampled when they contained at least three 
first-degree relatives with either breast or ovarian can­
cer, at least one of whom had been diagnosed at < 50  
years of age. Of the 176 families thus collected, there 
were 48 with at least four cases of breast cancer diag­
nosed at < 60  years of age and with any number of 
ovarian cancers. Approximately one-third of the re­
search families thus would meet current cancer-inci- 
dence eligibility criteria established by the Breast Cancer 
Linkage Consortium (Easton et ak 1995). Intake criteria 
for counseling families, as applied by the various centers, 
were heterogeneous both in terms of numbers and ages 
at onset of breast and ovarian cancers and in terms of 
the degree of kinship in the family. In general, families 
were offered DNA testing if their breast and/or ovarian 
cancer incidence suggested a ^10%  prior probability of 
being due to BRCA1 (Shattuck-Eidens et al. 1995). In 
addition, some centers forwarded isolated unilateral 
breast cancer cases, diagnosed at either < 40  years of 
age (Rotterdam) or < 35  years of age (Leiden and Am­
sterdam), or bilateral breast cancer cases in which the 
first primary cancer had occurred at < 40  years of age 
(Leiden). The center in Brussels used, as an additional 
criterion, at least two first-degree relatives with breast 
cancer diagnosed at < 6 0  years of age. Counseling fami­
lies were often less extensively sampled then research 
families. For all families, cancer diagnoses were con­
firmed by retrieval of pathology and/or medical records, 
wherever possible. Additionally, two DNA samples 
from Northern American families were included in the 
haplotype analysis. Both had the 2457C~»T mutation 
also found in the Dutch series, and one derived from 
the population-based Carolina Breast Cancer Study.
Blood samples from a consecutive series of 662 breast 
cancer patients were collected during the years 1 9 8 6 -  
94. These patients were diagnosed in two hospitals in 
the Leiden area and were not selected for either family 
history or age at onset. D NA samples were irreversibly 
anonymized before being subjected to BRCA1-mutation 
screening.
Genetic Studies
Human genomic D NA was isolated from either 20 ml 
EDTA or heparinized blood samples (Miller et al. 1988). 
Total RNA was isolated from either peripheral blood 
lymphocytes by use of either Histopaque 1077 (Sigma) 
or lysed erythrocytes, followed by RNAzol B extraction 
as described by the manufacturer (Cinna; Biotecx Labo­
ratories), Eight polymorphic microsatellite markers lo­
cated on chromosome 17q and spanning a 5.7-cM  inter­
val including BRCA1 were used in a radioactive PCR 
under conditions described elsewhere (Cornelis et al.
1995). From centromere to telomere, the order reported 
in the Genome Database (GDB) is as follows: D17S250, 
THRA1, D17S1321, D17S855, D17S1322, D17S1323, 
D17S1327, D17S579. Primer sequences to amplify these 
markers can be retrieved online from the GDB. A physi­
cal map for a number of these markers has been resolved 
(Neuhausen et al. 1996), and these distances (in kb)
are as follows: D 17S1321~(225 k b )-D 1 7 S 8 5 5 -(5  k b )-  
D 17S1322-(45  k b )-D 1 7 S 1 3 2 3 -(1 0 0  kb)-D 17S1327.
The sex-average genetic distance between THRA1 and
D17S579 is 3.2 cM (Easton et al. 1993). CEPH1347
was used as a reference to size alleles in terms of base 
pairs.
Screening for Mutations
A variety of methods were applied to detect the pres­
ence of a BRCA1 mutation in a total of 666 families 
(table 1). Chain-terminating mutations were screened 
for by the protein-truncation test (PTT) as described 
elsewhere (Hogervorst et al. 1995), with a nonradioac­
tive modification performed in some of the participating 
centers. Exon 11 was examined completely from geno­
mic DNA in virtually all of the families. When RNA  
was available, exons 2 - 1 0  also were screened by the 
PTT. One center used allele-specific oligonucleotide 
(ASO) hybridization, according to standard procedures 
(Saild et al. 1986), to screen for known exon 11 muta­
tions. Direct screening for deletions and insertions 
(DSDI) was performed with a multiplex PCR targeted 
at the mutations 185delAG (exon 2), 2804delAA (exon 
11), 4184del4 (exon 11), and 5382insC (exon 20). Four 
primer pairs were designed, producing PCR products of 
different sizes— 113, 130, 139, and 93 bp for the wild 
type of the four target sequences, respectively. Four mi­
croliters of 32P-dCTP-labeled PCR product were elec- 
trophoresed on a 6% polyacrylamide gel (7 M urea, 1 
X TBE) and were then fixed, dried, and exposed to a
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Table 1
Number of Families Screened, by Various Techniques, in Seven Dutch Centers and One Belgian Center
Tfx:i iNiguK
No. o r  Families N o . oi- 
M utations 
FoundLeiden Amsterdam Rotterdam Nijmegen Utrecht Groningen Maastricht Brussels Total
PTT, exon 11“ 106 123 52 59 36 35 56 23 490 44
PIT, exon I I 1’ 176 176 18
PTT, exons 2 -1 0 25 57 26 3 1 11 0
PTT exons 12-24 10 57 67 0
DSD Ie 138 56 194 5
DSDP1 50 50 1
ASO hybridization1' 13 1 131 6
T-tracking, exon 2 52 52 0
Sequencing exon 2 57 57 3
Sequencing exons
16—24 28 28 0
SSCP1 23 23 2
Families participated via family cancer clinics; all centers reported, on average, the same mutation rate,
11 Families were collected for research purposes.
c For mutations in exon 2, exon 11 (2804delAA and 4184del4), and exon 20. 
d For exons 2, 3, 5, 6, 20, 23, and 24.
c For mutations 185delAG, 14UinsT, 1438delT, 2312del5, 2457C->T, 2804delAA, 2841G->T, 2846del4,3604delA, 3668AG 
3939insG, and 3960C->T. 
f For exons 2, 5, and 20.
T, 3759G~>T,
Konica AX X-ray film. One center used DSDI for the 167-bp allele, reported in 13% of the Caucasian individ-
screening of exons 2, 3, 5, 6, 20, 23, and 24, using uals, was found in 32% of the Dutch control population,
fluorescently labeled primers and analysis on the Perkin The 165-bp allele was not found among controls,
Elmer ABI 373A automated sequencer in the GeneScan whereas the GDB reports a frequency of 13% in Cauca-
mode. One center screened exon 2, using the T-reaction sians. A discordancy in allele sizes was noted for
only in standard sequencing methodology. The Belgian TITRAI, for which we determined allele lengths to be
center used SSCP analysis to screen for mutations in an odd number of bases whereas the GDB reports even-
exons 2, 5, and 20. Primer sequences to obtain PCR numbered allele lengths, 
products and to detect the mutation of interest are either
retrievable electronically from the Breast Cancer Infor- Statistical Analysis 
mation Core (BIC) (1996) Web site (http://www.nhgn 
.nih.gov/Intramnral research/Lab o r
For dating the origin of the 2804delAA mutation, two 
algorithms were used— one developed to compute the age 
of the idiopathic torsion dystonia mutation in Ashkenazi 
Jews (Riseli et al. 1995) and one developed to derive the 
age of six BRGAI mutations (Neuhausen et ah 1996). 
Both give an estimate of the number of generations (G) 
since the origin of the mutation. G depends on the progeni­
tor marker-allele frequency in the normal population, the 
recombination fraction between the marker allele and the
available on request, for all applied methodologies. All 
mutations detected by the various screening methods 
were verified by direct sequencing using either a Phar­
macia ALF or Perkin Elmer ABI 373A or 377 automated 
sequencer and laser detection of fluorescently labeled 
primers or nucleotides, according to the suppliers’ pro­
tocols. Mutations were classified according to the no­
menclature recently proposed elsewhere (Beutler et al. disease locus, and Q, the observed frequency of disease 
1996), except for the 185delAG and 5382insC, to avoid chromosomes not carrying the progenitor marker allele, 
confusion with other publications concerning these com- The analysis was performed under the assumption that the
risk alleles for the flanking and intragenic microsatellite
markers were as follows; 167 bp (THRAl), 145 bp 
Allele Frequencies in the Dutch Population (D17S1321), 155 bp (D17S855), 133 bp (D17S1327),and
The allele frequencies at T H R A l, D17S855, and 119 bp (D17S579). The age was determined by use of
D17S579 were determined by typing a panel o f 168 either the physical distances (under the assumption that
unrelated Dutch control individuals. Obtained allele fre- 100 kb corresponds to a genetic distance of 0.1 cM) (Neu-
quencies were essentially comparable to those reported hausen et al. 1996) or the sex-average recombination frac-
in the GDB, except for some alleles of T H R A l. The tions (Easton et al. 1993). The sex-average distance be-
mon mutations.
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tween TH R A l and D17S579 is 3 ,2  cM, and the disease 
locus, coinciding with D 17S855, was assumed to lie half­
way between (Anderson et al. 1993).
Results
A total of 666  families were screened for the presence 
of a BRCA1 mutation, by use of a variety of m ethodolo­
gies, in seven different centers in the Netherlands and 
one center in Belgium. Exons 2  and 11 were most consis­
tently investigated (table 1). This revealed 79 families 
with a mutation (table 2), 8 o f which have been reported 
elsewhere (Hogervorst et aL 1995). Twenty-two families 
were found among the '176 collected for research pur­
poses, and the remaining 57 were among the 490 fami­
lies that are part of genetic-counseling programs, for 
which different intake criteria apply (see Subjects and 
M ethods). For each family, at least one individual with 
the highest probability o f being a gene carrier, generally 
an early-onset breast or ovarian cancer patient, was se­
lected for mutation testing.
Mutation Spectrum
The 79 mutations (table 2) comprise 28 different alter­
ations, 18 of which had not been reported in the BIC 
database (Couch et al. 1996) by investigators other than 
those participating in this study at the time that the manu­
script of this paper was submitted. The 12 recurrent muta­
tions accounted for 63 (80%) of the 79 families in which 
a BRCA1 mutation was detected. Most conspicuous was 
the occurrence of the 2804delAA mutation, which was 
observed in 19 families and has never been reported else­
where. Six Dutch centers reported families with this muta­
tion, and so they do not seem to cluster in a highly specific 
geographic area of the Netherlands. Similarly, the 
1411insT and 2312del5 mutations, found in seven and 
eight families, respectively, are novel and were found in 
different centers, These three mutations together thus com­
prise 34 (43%) of 79 families in which a mutation was 
detected. The known frequent mutations, 185delAG and 
5382insC, were found in eight and two families, respec­
tively, The Dutch BRCAl-mutation spectrum thus consists 
of a very high proportion of novel changes, relative to the 
spectrum currently available (Couch et al. 1996). Since the
Table 2
Dutch and Belgian BRCA1 Mutations
Mutation Effect on Protein No. of Families
Reported outside 
Netherlands/Belgium?a
185delAG Asn 23 end 39 8 Y
Unknown Cys 64 end 310 (RNA) 1 N
IVS5+3A-+G del exon 5 1 N
113 5 de IA Val 339 end 340 1 N
1135insA Val 339 end 345 1 Y
"J 240del C T hr 374 end 376 1 Y
140 Gins A G lu 430 end 434 2 N
'141 linsT Leti 431 end 434 7 N
I438deIT Leu 440 end 439 2 N
1623del5 Leu 502 end 505 1 Y
2140delC Leu 674 end 699 1 N
2312de! 5 Glu 732 end 736 8 N
2331dcl4 Val 738 end 751 1 N
2457C->T Gin 780 end 779 3 Y
2804delAA Gin 895 end 901 19 N
2841 G-^T Glu 908 end 908 3 Y
2846do 14 Asn 909 end 998 1 N
3109insAA Asn 998 end 1001 2 N
3604del A Asp 1162 end 1209 4 Y
3668AG-+T Lys 1138 end 1209 1 N
3759 G-►T Glu 1214 end '1214 1 N
3780G-*T Glu 1221 end 1221 1 N
3867G-+T Glu 1250 end 1250 1 Y
3875 de 14 Leu 1252 end 1262 1 Y
3939insG Val 1274 end 1286 3 N
3960C-*T Gin 1281 end 1281 1 Y
5382insC Gin 1756 end 1892 2 Y
5389deI7 Asp 1796 end 1800 1 N
1 As in the BIC database, as of December 15, 1996 (Breast Cancer Information Core 1996), Y = yes; and 
N «  no,
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2804delAA mutation alone comprises 24% of all muta­
tions found, we investigated its incidence by DSDI among 
a series of 662 breast cancer patients, consecutively col- 
lected and unselected for either family history or age at 
onset. One patient, who had breast cancer at 4 1 -4 5  years 
of age, was found to carry the mutation in lymphocyte 
DNA. The 185delAG, 4184del4, and 5282insC mutations 
were not found.
Haplotype Analysis
Disease-associated haplotypes of 9 of the 12 recurrent 
mutations were reconstructed by typing three intragenic 
markers (D17S855, D17S1322, and D17S1323) and five 
flanking markers (table 3). For the 2804delAA muta­
tion, this analysis was completed in 18 of 19 families, 
and unambiguous phasing of disease haplotypes at the 
three intragenic markers was possible in 8 of them. 
These families were completely concordant for the 155- 
122-151 haplotype. In at least three families, haplotype 
conservation extended proximally to D17S250, but 
D17S579 at the distal end was recombinant in all three. 
The 156-, 122-, and 151-bp alleles at D17S855, 
D17S1322, and D17S1323, respectively, were observed 
in all 18 families with the 2804delAA mutation, and the 
same was true for both the 145-bp allele at D17S1321 
and the 133-bp allele at D17S1327. This indicates that a 
segment is conserved among 8 families— and, possibly, 
among all 18 families— and spans a region between 375 
kb (defined by D17S1321 and D17S1327) and 3.2 cM 
(defined by TH R A l and D17S579).
The shared haplotypes among five families with the 
185delAG mutation cover the same region as that shared 
among the 2804delAA-mutation carriers (table 3). It is 
noteworthy that the linked alleles at the intragenic mark­
ers D17S1321, D17S855, and D17S1327 are identical
to the previously reported disease-associated alleles for 
Ashkenazi Jewish families carrying the 185delAG muta­
tion (Simard et al. '1994). For families with the 2312del5 
and 141 linsT  mutations, the shared haplotype also 
might extend from TH R A l to D17S579. However, 
among seven families with the 2312del5 mutation, 
D17S855 differs, with one dinucleotide (CA) repeat unit 
from the most commonly shared allele, in one family 
(RUL57). Likewise, among five families with the 
141 linsT mutation, a three-(CA)-unit difference was 
noted at D17S1323 in family B7489. Given the allele 
lengths at flanking markers in family RUL57, a mutation 
in the repeat block is the most likely explanation for 
this difference (Weber and Wong 1993; Neuhausen et 
al. 1996); in B7489 a recombination event cannot be 
fully excluded. Finally, the haplotypes associated with 
any of the other mutations that were found more than 
once also suggested that they each have a common origin
(table 3). The 2457C-+T mutation, which was found
three times in the Netherlands, was also reported in two 
Northern American families (Friedman et al. 1995; B.
Newman, unpublished data). Analysis of the disease- 
carrying haplotype nonetheless supported a common or­
igin. The index case of one of these families reported a 
Dutch ancestry; the other is of unknown but supposedly 
western European ethnic background.
Age at Origin o f the 2804delAA Mutation
The allele frequencies of THRAl, D17S855, and 
D17S579 were determined in a control population of 
168 individuals (data not shown). The frequency of the 
155-bp allele atD17S855 was 7%. Since the2804deIAA  
mutation is associated with this allele in at least eight 
kindreds, this makes it extremely unlikely that the muta­
tion occurred twice independently on the same haplo- 
type.
By use of THRAl and the disease locus (coincident 
with D17S855) at a genetic distance of 1.6 cM, the 
origin of the mutation was estimated to have been ~ 1 5  
generations ago. However, when D17S579 was used 
(also at 1.6 cM), the estimated age was 49 generations. 
The average number of generations when data from 
both markers were used was 32. When the algorithm 
developed by Goldgar and coworkers (Neuhausen et al. 
1996) was used on the same data set, 35 generations 
were derived (1-LOD-unit support interval = 1 4 -5 9 ), 
with .97 being the estimated proportion of families due 
to the mutation occurring on the presumed ancestral 
haplotype.
Genotype-Phenotype Correlation
Table 4 lists the incidence of breast and ovarian cancer 
in the families with any one of the five most frequently 
found mutations. Among 18 families carrying the 
2804delAA mutation, a heterogeneous phenotype was 
observed. Some families had only breast cancer, with 
or without bilateral incidence; others contained either 
ovarian cancer cases only or both breast and ovarian 
cancer cases. A remarkable paucity of ovarian cancer 
relative to breast cancer was observed in the families 
with the 2457C-*T mutation. Also, the families with 
either the 185delAG, 2312del5, or 141 linsT mutation 
did not show a consistent phenotype, in terms of breast 
or ovarian cancer incidence.
Discussion
We have screened > 650  Dutch and Belgian breast 
and ovarian cancer families for the presence of gene 
alterations in BRCAl and have found that, of the 28 
distinct mutations detected in 79 families, 18 have not 
been reported elsewhere. In addition, 12 mutations were 
found more than once in a total of 63 families (80%). 
Although difficult to compare, the proportion of muta­
tions accounted for by the 185delAG mutation and 
5382insC was not significantly different from that re­
ported in other studies (Shattuck-Eidens et al. 1995;
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Table 3
Haplotypîng of 47 Dutch and Belgian BRCAl Families
H a p l o t y p e  a t  M a r k e r
M u t a t io n  
a n d  F a m il y D17S250 THRAl D17S1321 D17S855 D17S1322 D17S1323 D17S1327 D17S579
2804delAA:
RUL60 164 167 145 155 122 151 133 119
MOC52 164 167 145 155 122 151 133 111
PFT8 164 167 145 155 122 151 133 127
N3172 156-166 177-179 145 155 122 151 133 119-113
MOC440 164-162 167 145-155 155 122 151 133 127
MOC493 164-152 167-169 145 155 122 151 133 119-113
MOC506 164-156 167 145-155 155 122 151 133 111-129
EUR 13 164 167-173 145-155 155 122 151 133 119-129
MOC66 164-152 167-169 145-153 155-147 122-128 151 133-157 125-127
RUL82 154 171 145 155 122-125 1.51 133 119
B5513 164 167 145 155 122 151-157 133 119
MOC 559 164-162 167 145 155-145 122-125 151-159 133-167 119-127
B7178 152-154 171 145-155 155-147 122-125 151-157 133-159 111-123
PFT7 '164-158 167 145 155-145 122-125 151-157 133-161 111
B7533 152-164 167-171 145-149 155-145 122-125 151-157 133-157 109-113
G394 162-168 167-175 145-155 155-151 122 151 133 119-131
U644 —- 171-159 1.45-153 155-151 122 151 133 ---
U484 -- 167 145-155 155-143 122-125 151-157 133-165 121-123
185delAG:
RUL85 156 177 155 145 128 157 163 113-121
RUL26 158 167 155 145 128-122 157-151 163 123
RUL101 150 167 155 145 128 157 163 113
N3538 152-154 171-173 155-157 145-151 128-122 157-151 163-133 113-115
B7219 160 167 155-145 145 128 157 163 123
2312del5:
RUL21 150 181 145 149 122 151 133 125
RUL57 164-154 171 145 147 122 151 133 125
MOC580 164 171 145-163 149 122 151 133 121
N3507 152-156 171-175 145 149-151 122-119 151 133 121-125
BEL030 164-152 171 145-147 149 122-128 151-157 133 125
BEL049 -- 171 145 149 122-125 151 133 125-113
PFT135 -— 181-175 145-147 149-143 122-125 151 133 ---
141 linsT;
EURI 7 150 175 153 145 122-125 151-159 161 111
EUR33 150 175 153 145 125 159 161 123
MOC549 150 175 153 145 125 159-157 161 123
M51013 150-160 175-171 153-151 145-151 125-122 159-151 1.61-133 123-121
B7489 154 171 153 145 125 153 161 111-125
2457C->T:
1
RUL47 —- 171 149 145 131 157 167 125
RUL49 — 171 149 145 131 157 167 117
FAM7 -- 171 149 145 131 157 167 117
930654 ,--. 171 149 145 128-122 157 167 115-123
1438delT:
MOC46 -- 169 157 153 122 151 133 125
PFT9 -- 169-175 -- 149-153 122-125 151 133 125-129
3604delA:
MOC662 -- - 167 -- 145 128 157 133 111-113
N3110 -- - 161-171 145 145-151 122-131 157-151 133-165 121-125
3939insG:
MOC3 --- 145 147-153 145-153 122 151 133 123-117
RUL77 --« 145 143 145 1.22 151 133 123
5382insC;
EUR5 -- 167 153 151 122 151 129 121
BEL002 --- 169-171 149-153 151-145 122-125 151-157 129-167 115-127
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Table 4
Incidence of Breast and Ovarian Cancer in Families Carrying One of the More Frequent Founder Mutations
M u t a t io n
N o . o f  C a s e s"
N o . o f  Fam ilies
Breast Cancer Only Ovarian Cancer Only
Breast and 
Ovarian CancerBreast Cancerb Ovarian Cancer
185delAG 24 (13) 8(4) 4 0 4
141 linsT 23 (20) 8(8) 2 1 4
2312del5 9(9) 7(4) 3 1 2
2457C-*T 24c (22) 6(5) 1 0 3
2804delAA 36 (22) 19 (9) 7 5 6
“ Numbers in parentheses are number of cases for which pathological or medical records were available. 
b Bilateral breast cancer cases were counted as two separate primary breast tumors. 
c Includes one case of male breast cancer.
Couch et al. 1996). These mutations are particularly mutation spectrum genuinely derives from a Dutch Cau- 
frequent among Ashkenazi Jews (Roa et al. 1996). The casian White population.
families under study here have not been selected for It is difficult to estimate how representative this spec-
ethnic background, although two families with the trum is of the general Dutch population. In none of the 
185delAG mutation were reported to be of Jewish ori- centers did the mutation-screening approach cover the
gin. The 4184del4 mutation, which frequently is found 
among breast-ovarian cancer families in the United 
Kingdom (Gayther et al. 1995) and which would be
complete coding region, and the possibility that other 
frequent but as yet unknown mutations exist among the 
breast cancer families studied here cannot be excluded.
missed by our PTT, was not detected in any Dutch fam- In particular, since PTT was the most broadly used
ily by DSDI. Our results thus add further weight to the screening module, we will have underestimated the inci-
concept that the proportions of specific BRCAl muta- dence of missense mutations. Yet, for exon 11, we prob-
tions are strongly dependent on the ethnic background ably have obtained a representative mutation set, since
of the study population. Specific and novel mutations in 94% of all exon 11 mutations lead to premature chain
BRCAl also have been detected in Swedish, Austrian, termination during translation (Couch et al. 1996), and
Norwegian, and Italian families (Andersen et al. 1996; 90% of the 3.4-kb exon is screened reliably by PTT
Caligo et al. 1996; Johannsson et al. 1996; Wagner et (Van der Luijt et al. 1994; Hogervorst et al. 1995), A
al. 1996). This will have important consequences for the selection for families whose cancer incidence has a high
routine of genetic testing, for which assessing the ethnic prior probability of being due to BRCAl, in the presence
origin of the index case may direct mutation screening of a genotype-phenotype correlation, also might affect
to specific regions of the gene. the mutation spectrum. The intake criteria applied for
The Netherlands and Belgium, are neighboring coun- research families were different than those applied for 
tries and occupy a relatively small geographic area of families asking for genetic advice via genetic-counseling 
northwestern Europe. Until ~ 1 5 0  years ago, the Flemish centers. Both criteria are expected to give rise to a mix-
part of Belgium and the Netherlands formed one nation. 
Their joint current population of ~ 2 0  million has re-
ture of high- to medium-risk families with considerable 
but partial overlap. For example, two sisters each diag-
mained fairly immobile and isolated until post-Second nosed with breast cancer at < 40  years of age would
World War times. These conditions may have led to the not be eligible under the research criteria but would be
fixation of quite a distinct spectrum of BRCAl muta- eligible under the counseling criteria. Intriguingly, the
tions. It is noteworthy that the 3604delA mutation re- BRCAl mutation-identification rate in both groups of
ported here was submitted recently to the BIC database families was approximately the same. This rate is lower
by a group from Düsseldorf, just across the Netherlands’ than those reported by others, but those studies have
border, but has not yet been reported outside this region. selected families on the basis of linkage analysis and/or
Although the Dutch population contains substantial eth- ovarian cancer incidence (Castilla et al. 1994; Friedman
nie minorities from Indonesia, Turkey, Morocco, and et al. '1994; Struewing et al. 1995b; Gayther et al. 1995;
Surinam, the age at origin of BRCAl mutations likely Serova et al. 1996), which will strongly increase the
predates their recent immigrations, and families with proportion due to BRCAl. A complete description of
these backgrounds are very rarely seen in family-cancer 
clinics. We are convinced therefore that the obtained
all families, in terms of breast and ovarian cancer inci­
dence, in conjunction with a complete screening of the
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entire BRCAl coding region, would be required in order 
to resolve this.
Haplotype analysis of 9 of the 12 recurrent mutations 
indicated strong founder effects, in particular for those 
mutations that occurred more than five times. At the 
intragenic markers, the obtained haplotypes for the 
185delAG mutation were identical to those reported 
elsewhere (Simard et al. 1994; Friedman et al. 1995).
Except for two families, we were unable to retrieve evi­
dence that the families with the 185delAG are of Ash­
kenazi Jewish origin, but this mutation has been esti­
mated to have arisen ~ 3 8  generations, or ~ 7 6 0 years, 
ago (Neuhausen et al. 1996). Several waves of eastern 
European immigrants during several centuries therefore 
render it conceivable that this mutation also migrated to 
the Netherlands. Intriguingly, the 2804delAA mutation 
appears to have arisen at approximately the same time. 
It is striking that the haplotypes carrying any one of 
the nine recurrent mutations investigated here are all 
in agreement with the possibility that they each have 
descended from a common ancestor. This is in contrast 
with haplotype data obtained on the 185delAG and 
4184del4 mutations, which provide evidence for multi­
ple, independent mutational events (Berman et al. 1996; 
Neuhausen et al. 1996). Our data nonetheless suggest 
that a considerable number of the mutations known to 
date, including the ones that occur less frequently but 
particularly those that are unique to certain geographic 
areas, might have arisen once. It should be noted that 
no de novo BRCAl mutation has been reported yet, and 
our data and those of others (Neuhausen et al, 1996) 
suggest that these mutations will be extremely rare.
The 2804delAA mutation, although accounting for 
24% of all mutations in the families studied here, was 
found only once among 662 breast cancer cases consecu­
tively collected in the Leiden area and unselected for 
either age at diagnosis or family history. If the mutation 
distribution found in these families also applies to unse­
lected cases, and if we correct for the fact that an esti­
mated 60 % of the current mutation spectrum in the BIC 
would have been identified by our screening protocols, 
then the estimated population gene frequency of BRCAl 
(Ford et al. 1995) predicts 1.6 carriers among 662 cases 
(1.7% X 24% X  60% X 662), This suggests that the 
frequency of BRCAl in the Dutch population is not 
higher than that estimated by linkage (Fordetal. 1995) 
and that the high proportion of the 2804delAA mutation 
is due mainly to the founder effect. Although the muta­
tion was identified by six centers located in all corners 
of the Netherlands, this area is still small relative to the 
whole of Europe, which would be in agreement with the 
low migration rates of the Dutch.
N o  consistent phenotype, as defined by occurrence of 
breast and ovarian cancer (table 4), could be discerned 
among 18 families with the 2804delAA mutation. Some 
families contained breast cancer cases only, and others
contained only ovarian cancer cases, although the num­
ber of cases per family was small because many were 
ascertained through family-cancer clinics. For the five 
most frequently encountered mutations, the breastrov- 
arian cancer-incidence ratio was 2.5 (table 4), in agree­
ment with our observations elsewhere (Peelen et al.
1996). Friedman et al, ('1995) also found that the expres­
sivity of the 185delAG mutation varies, from early-onset 
breast cancer and ovarian cancer to late-onset breast 
cancer without ovarian cancer. Linkage analysis has in­
dicated that ovarian cancer risk in BRCAl-linked fami­
lies is heterogeneous (Ford et al. 1994). Subsequently, 
mutations occurring before codon 1435 in exon '13 were 
found to confer a significantly higher ovarian cancer 
risk than was found in those occurring after this point 
(Gayther et al, 1995), We cannot confirm this observa­
tion here, mainly because almost all mutations occur 
before codon 1435, Yet, we found 13 families in which 
only breast cancer was ascertained that are not in agree­
ment with it, most conspicuously the families with the 
2457C-^T mutation. Alternatively, a genetic modifier of 
ovarian cancer risk might exist that is closely linked to 
BRCAl. It therefore will be of interest to more accu­
rately determine the extent and overlap of the shared 
haplotype among families with an identical mutation 
but with distinct phenotypes or different ethnic back­
grounds.
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